Expired CME Article

Chronic Kidney Disease: Whom to Screen and How to Treat, Part 1: Definition, Epidemiology, and Laboratory Testing

Authors: Godela Brosnahan, MD, Mony Fraer, MD

Abstract

Chronic kidney disease has become a major public health problem due to its high prevalence, its exorbitant cost, and large reductions in life expectancy and quality of life of affected people. Seventy percent of cases of end-stage renal disease are due to diabetes and hypertension, conditions which are usually managed by primary care providers. Other risk factors are cardiovascular disease, obesity, smoking, family history of kidney disease, and age greater than 55 years. Patients with these risk factors should be evaluated for the presence of chronic kidney disease during their primary care visits, because effective treatments for slowing progression are available, particularly if instituted early. Chronic kidney disease can be diagnosed by simple blood and urine tests, as recommended in guidelines issued by the National Kidney Foundation. This article begins with a case vignette, representing a common clinical scenario from a general internist's practice. We then review the definition and classification of chronic kidney disease, the epidemiology, etiology, and interconnections with cardiovascular disease. We discuss the guidelines for screening and laboratory testing, as well as the limitations of current assessment tools. A subsequent article will review evidence-based management of chronic kidney disease.


Key Points


* CKD is common: up to 13% of the general population and over 30% of the elderly may be affected.


* Risk factors for CKD are diabetes, hypertension, cardiovascular disease, obesity, and age.


* CKD is associated with high cardiovascular morbidity and mortality, similar to diabetes.


* Screening tests are urine albumin-to-creatinine ratio and a serum creatinine level. Use of an estimating equation for glomerular filtration rate (GFR) is preferred over a simple serum creatinine level for the assessment and staging of CKD.


* Screen all patients with an estimated GFR less than 60 mL/min/1.73 m2 (ie CKD stage 3–5) for anemia. If anemia is found, obtain serum iron saturation, ferritin, vitamin B12 and folate levels.


* Check a fasting lipid panel, serum calcium, phosphorus, bicarbonate and PTH level in all patients with CKD.

This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1.Levey AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem: approaches and initiatives—a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007;72:247–259. (KDIGO position statement)
 
2.Coresh J, Stevens LA, Levey AS. Chronic kidney disease is common: what do we do next? Nephrol Dial Transplant 2008;23:1122–1125. (Commentary)
 
3.Foley RN, Collins AJ. End-stage renal disease in the United States: an update from the United States Renal Data System. J Am Soc Nephrol 2007;18:2644–2648. (Review of national database; 472,000 subjects)
 
4.Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038–2047. (Cross-sectional study; 28,721 subjects)
 
5.US Renal Data System. USRDS 2007 Annual Data Report: Atlas of End-stage Renal Disease in the United States. Bethesda, MD, National Institutes of Health, 2007. (Report of national database; 472,000 subjects)
 
6.Levey AS, Schoolwerth AC, Burrows NR, et al. Comprehensive public health strategies for preventing the development, progression, and complications of CKD: report of an expert panel convened by the Centers for Disease Control and Prevention. Am J Kidney Dis 2009;53:522–535. (Special report)
 
7.National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;36(2 suppl 1):S1–S266. (Clinical practice guidelines)
 
8.Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in Renal Disease Study Group. Ann Intern Med 1999;130:461–470. (Cross-sectional analysis of baseline data of 1628 patients from a randomized controlled trial)
 
9.Levey AS, Greene T, Kusek J, et al. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000;11:828A (abstract). (Cross-sectional analysis of baseline data of 1628 patients from a randomized controlled trial)
 
10.European Best Practice Guidelines Expert Group on Hemodialysis; European Renal Association. Section. I. Measurement of renal function, when to refer and when to start dialysis. Nephrol Dial Transplant 2002;17(suppl 7):7–15. (Clinical practice guidelines)
 
11.Hallan S, Asberg A, Lindberg M, et al. Validation of the modification of diet in renal disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay. Am J Kidney Dis 2004;44:84–93. (Cross-sectional study; 215 patients)
 
12.Stevens LA, Coresh J, Greene T, et al. Assessing kidney function—measured and estimated glomerular filtration rate. N Engl J Med 2006;354:2473–2483. (Review)
 
13.Rule AD, Gussak HM, Pond GR, et al. Measured and estimated GFR in healthy potential kidney donors. Am J Kidney Dis 2004;43:112–119. (Cross-sectional study; 365 subjects)
 
14.Stevens LA, Coresh J, Feldman HI, et al. Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol 2007;18:2749–2757. (Cross-sectional study; 5504 subjects)
 
15.Zhang L, Zhang P, Wang F, et al. Prevalence and factors associated with CKD: a population study from Beijing. Am J Kidney Dis 2008;51:373–384. (Cross-sectional study; 13,925 subjects)
 
16.Chadban SJ, Briganti EM, Kerr PG, et al. Prevalence of kidney damage in Australian adults: the AusDiab kidney Study. J Am Soc Nephrol 2003;14:S131–S138. (Cross-sectional study; 11,247 subjects)
 
17.Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health 2008;8:117. (Systematic review of 26 studies)
 
18.Campbell KH, O'Hare AM. Kidney disease in the elderly: update on recent literature. Curr Opin Nephrol Hypertens 2008;17:298–303. (Review)
 
19.Hemmelgarn BR, Zhang J, Manns BJ, et al. Progression of kidney dysfunction in the community-dwelling elderly. Kidney Int 2006;69:2155–2161. (Prospective cohort study; 10184 subjects)
 
20.Eriksen BO, Ingebretsen OC. The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age. Kidney Int 2006;69:375–382. (Prospective cohort study; 3047 patients)
 
21.O'Hare AM, Choi AI, Bertenthal D, et al. Age affects outcomes in chronic kidney disease. J Am Soc Nephrol 2007;18:2758–2765. (Prospective cohort study; 209,622 patients)
 
22.Bauer C, Melamed ML, Hostetter TH. Staging of chronic kidney disease: time for a course correction. J Am Soc Nephrol 2008;19:844–846. (Clinical commentary)
 
23.Wen CP, Cheng TY, Tsai MK, et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet 2008;371:2173–2182. (Prospective cohort study; 462,293 subjects)
 
24.McClellan W, Warnock DG, McClure L, et al. Racial differences in the prevalence of chronic kidney disease among participants in the reasons for geographic and racial differences in Stroke (REGARDS) cohort study. J Am Soc Nephrol 2006;17:1710–1715. (Cross-sectional analysis of baseline data of a prospective cohort study; 20,667 subjects)
 
25.Astor BC, Hallan SI, Miller ER III, et al. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol 2008;167:1226–1234. (13 year follow-up of cross-sectional study; 14,586 subjects)
 
26.Henry RM, Kostense PJ, Bos G, et al. Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn Study. Kidney Int 2002;62:1402–1407. (Prospective cohort study: 631 subjects)
 
27.Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003;41:47–55. (Prospective cohort study; 15,350 subjects)
 
28.Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004;15:1307–1315. (Pooled analysis of 4 prospective community-based cohort studies; total of 22,634 subjects)
 
29.Go SA, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events and hospitalization. N Engl J Med 2004;351:1296–1305. (Retrospective cohort study; 1,120,295 subjects)
 
30.Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006;17:2034–2047. (Systematic review of 39 studies; 1,371,990 subjects)
 
31.Keith D, Nichols GA, Gullion CM, et al. Longitudinal follow up and outcome among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004;164:659–663. (Prospective cohort study; 27,998 patients)
 
32.Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 2003;108:2154–2169. (AHA scientific statement)
 
33.Muntner P, He J, Astor BC, et al. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005;16:529–538. (Prospective cohort study: 807 subjects)
 
34.Levin A. Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis. Semin Dial 2003;16:101–105. (Review)
 
35.Shishehbor MH, Oliveira LP, Lauer MS, et al. Emerging cardiovascular risk factors that account for a significant portion of attributable mortality risk in chronic kidney disease. Am J Cardiol 2008;101:1741–1746. (Prospective cohort study: 4,680 patients)
 
36.O'Hare AM, Bertenthal D, Shlipak MG, et al. Impact of renal insufficiency on mortality in advanced lower extremity peripheral arterial disease. J Am Soc Nephrol 2005;16:514–519. (Prospective cohort study; 5787 patients)
 
37.Nickolas TL, Khatri M, Boden-Albala B, et al. The association between kidney disease and cardiovascular risk in a multiethnic cohort: findings from the Northern Manhattan Study (NOMAS). Stroke 2008;39:2876–2879. (Prospective cohort study; 3298 patients)
 
38.Hallan SI, Dahl K, Oien CM, et al. Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey. BMJ 2006;333:1047–1052. (8 year follow-up of a cross-sectional study; 65,604 subjects)
 
39.Zhang L, Zuo L, Xu G, et al. Community-based screening for chronic kidney disease among populations older than 40 years in Beijing. Nephrol Dial Transplant 2007;22:1093–1099. (Cross-sectional study; 2353 subjects)
 
40.Cusumano AM, Gonzalez Bedat MC. Chronic kidney disease in Latin America: time to improve screening and detection. Clin J Am Soc Nephrol 2008;3:594–600. (Review of national health surveys of Latin American countries)
 
41.Yamagata K, Iseki K, Nitta K, et al. Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin Exp Nephrol 2008;12:1–8. (Review)
 
42.De Jong PE, van der Velde M, Gansevoort RT, et al. Screening for chronic kidney disease: where does Europe go? Clin J Am Soc Nephrol 2008;3:616–623. (Review)
 
43.Vassalotti JA, Stevens LA, Levey AS. Testing for chronic kidney disease: a position statement from the National Kidney Foundation. Am J Kidney Dis 2007;50:169–180. (Position statement; clinical practice guidelines)
 
44.Rossert JA, Wauters JP. Recommendations for the screening and management of patients with chronic kidney disease. Nephrol Dial Transplant 2002;17(suppl 1):19–28. (Clinical practice guidelines)
 
45.KDOQI; National Kidney Foundation. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis 2006;47(suppl 3):S16–S85. (Clinical practice guidelines)
 
46.Locatelli F, Aljama P, Bárány P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19 (suppl 2):ii1–ii47. (Clinical practice guidelines)
 
47.National Kidney Foundation; K/DOQ Group. K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis 2003;41(suppl 3):S1–S91. (Clinical practice guidelines)
 
48.National Kidney Foundation; K/DOQ Group. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:S1–S201. (Clinical practice guidelines)
 
49.Glassock RJ, Winearls CG. eGFR: readjusting its rating. Clin J Am Soc Nephrol 2009;4:867–869. (Commentary)
 
50.Botev R, Mallie JP, Couchoud C, et al. Estimating glomerular filtration rate: Cockcroft-Gault and Modification of diet in renal disease formulas compared to renal inulin clearance. Clin J Am Soc Nephrol 2009;4:899–906. (Pooled analysis of existing data from research studies and clinical populations; 2208 patients)
 
51.Macdonald J, Marcora S, Jibani M, et al. GFR estimation using cystatin C is not independent of body composition. Am J Kidney Dis 2006;48:712–719. (Cross-sectional study; 77 patients)
 
52.Stevens LA, Coresh J, Schmid CH, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008;51:395–406. (Pooled analysis of existing data from research studies and clinical populations; 3,418 patients)
 
53.Levey AS, Stevens LA, Schmid CH, et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604–612. (Cross-sectional analysis; 12,150 subjects)